Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some elements (BH4-responsive PKU indication, need for evaluation/biochemical response via blood Phe monitoring, and dose escalation/discontinuation logic) partially align with the provided label excerpts. However, multiple claims about specific clinical triggers (developmental delay, autism-like traits, behavioral problems, seizures/tremor/poor coordination) and newborn symptom prevention are not supported by the provided prescribing-information excerpts. The specific dosing regimen and responder definition are also not fully supported as stated.
Category Scores
Accurate Statements
Sapropterin is considered for phenylketonuria (PKU) patients with hyperphenylalaninemia.
Supported in general by Indications: JAVYGTOR is indicated to reduce blood Phe levels in adult and pediatric patients with hyperphenylalaninemia (HPA) due to BH4-responsive PKU.
Responders continue sapropterin therapy alongside diet.
Partially supported: Dosage/Administration states the diet (Phe-restricted) is used in conjunction; it also states dosage may be adjusted once responsiveness is established (implying continuation).
Unsupported Statements
Sapropterin is considered when blood phenylalanine (Phe) levels are above 10 mg/dL (600 μmol/L) despite dietary management.
The provided label excerpts do not mention a threshold of 10 mg/dL (600 μmol/L) for initiating or considering sapropterin.
Sapropterin evaluation is prompted by developmental delays or cognitive impairment from chronic high Phe.
The provided label excerpts do not state that developmental delay/cognitive impairment is an evaluation trigger for JAVYGTOR.
Sapropterin evaluation is prompted by behavioral problems such as hyperactivity, anxiety, or autism-like traits.
The provided label excerpts only mention monitoring for hyperactivity as a precaution/adverse reaction; they do not support using behavioral problems (anxiety/autism-like traits) as triggers for evaluation.
Sapropterin evaluation is prompted by neurological signs such as seizures, tremors, or poor coordination.
The provided label excerpts do not describe these neurological signs as triggers for evaluation. While levodopa-related monitoring mentions seizures/exacerbation of seizures in that specific drug context, it is not stated as a general evaluation prompt for sapropterin.
In newborns, elevated Phe detected via screening can prevent symptoms such as musty breath odor, eczema, or fair skin/hair.
The provided label excerpts do not state that newborn screening/elevated Phe detection and treatment with sapropterin prevents these specific symptoms.
A 4-week sapropterin challenge involves taking 20 mg/kg/day.
The provided label excerpt describes an evaluation period up to 1 month at 10 mg/kg/day and dose increase to 20 mg/kg/day if blood Phe does not decrease at 10 mg/kg/day; it does not explicitly specify a 4-week challenge at 20 mg/kg/day for all patients.
Patients are considered responders to sapropterin if Phe drops by at least 30% during the trial.
The provided label excerpts do not define a responder threshold such as ≥30% reduction in blood Phe.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
If a 10 mg/kg/day starting dose is used, response determination is based on change in blood Phe after treatment at 10 mg/kg/day for up to 1 month, with blood Phe checked after 1 week and periodically for up to a month; if no decrease, dose may be increased to 20 mg/kg/day, and if still no decrease after 1 month at 20 mg/kg/day, discontinue.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported initiation/evaluation triggers and an unlabelled responder definition/threshold could lead to inaccurate clinical decision-making if followed. The dosing description may be imprecise relative to the label’s evaluation and discontinuation logic.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts (specific Phe thresholds, evaluation triggers from developmental/behavioral/neurological symptoms, newborn symptom prevention, and a specific 4-week 20 mg/kg/day challenge and ≥30% responder criterion).
Suggested Improvement
Align statements to the label excerpts by: (1) describing indication as reducing blood Phe in BH4-responsive PKU with a Phe-restricted diet; (2) stating that responsiveness cannot be pre-determined and must be determined via a therapeutic trial with blood Phe monitoring, with dosing per label (10 mg/kg/day starting, possible increase to 20 mg/kg/day if no decrease, and discontinuation if no biochemical response after 1 month at 20 mg/kg/day); and (3) removing or reframing claims that are not present in the provided prescribing-information excerpts.